An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels. (Q53126117)
Jump to navigation
Jump to search
scientific article published on 7 January 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels. |
scientific article published on 7 January 2013 |
Statements
An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels. (English)
Thies Rösner
Stefanie Derer
Michael Dechant
Stefan Lohse
Matthias Peipp
Thomas Valerius
7 January 2013
161
2
282-286
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference